Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Enterprise Value (2016 - 2025)

Syndax Pharmaceuticals has reported Enterprise Value over the past 11 years, most recently at -$154.5 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$154.5 million for Q4 2025, up 73.02% from a year ago — trailing twelve months through Dec 2025 was -$154.5 million (up 73.02% YoY), and the annual figure for FY2025 was -$154.5 million, up 73.02%.
  • Enterprise Value for Q4 2025 was -$154.5 million at Syndax Pharmaceuticals, up from -$436.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for SNDX hit a ceiling of -$63.3 million in Q1 2023 and a floor of -$572.9 million in Q4 2024.
  • Median Enterprise Value over the past 5 years was -$180.0 million (2022), compared with a mean of -$242.3 million.
  • Biggest five-year swings in Enterprise Value: tumbled 666.34% in 2023 and later soared 73.02% in 2025.
  • Syndax Pharmaceuticals' Enterprise Value stood at -$222.2 million in 2021, then skyrocketed by 66.48% to -$74.5 million in 2022, then tumbled by 666.34% to -$570.7 million in 2023, then fell by 0.38% to -$572.9 million in 2024, then soared by 73.02% to -$154.5 million in 2025.
  • The last three reported values for Enterprise Value were -$154.5 million (Q4 2025), -$436.0 million (Q3 2025), and -$455.2 million (Q2 2025) per Business Quant data.